Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[General principles of dose-effect relationship].

C Borg1, V Trillet-Lenoir

  • 1Unité fonctionnelle d'oncologie médicale, Centre hospitalier Lyon-Sud, 69495 Pierre-Bénite Cedex.

Bulletin Du Cancer
|October 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.

ESMO gastrointestinal oncology·2026
Same author

Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial.

ESMO gastrointestinal oncology·2026
Same author

Authors' reply to the Letters to the Editor discussing main outcomes of the PRODIGE 23 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.

Frontiers in immunology·2023
Same author

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.

British journal of cancer·2022

Chemotherapy intensification, considering dose response, density, and intensity, is reconsidered due to treatment limits and improved hematopoietic support. Mathematical models inform these intensified therapeutic strategies for better cancer treatment outcomes.

Area of Science:

  • Oncology
  • Mathematical Biology
  • Pharmacology

Context:

  • Chemotherapy administration principles are historically linked to hematological toxicity.
  • Mathematical models by Goldie and Coldman (1979) and Norton and Simon established dose-response relationships in chemotherapy.
  • Clinical limitations and advancements in hematopoietic support necessitate re-evaluation of treatment intensity.

Purpose:

  • To review the theoretical foundations of therapeutic intensification in cancer treatment.
  • To explain the concepts of dose-response, dose-density, and dose-intensity in chemotherapy.
  • To provide context for clinical applications of intensified chemotherapy regimens.

Summary:

  • This chapter revisits the theoretical basis of chemotherapy administration, focusing on dose-response, dose-density, and dose-intensity.

Related Experiment Videos

  • It highlights the evolution of mathematical models in understanding chemotherapy's cytotoxic effects and tumor growth dynamics.
  • The principles are discussed in light of current clinical challenges and supportive care advancements.

    • Impact:

    • Provides a foundational understanding for clinicians considering intensified chemotherapy.
    • Informs the strategic application of dose adjustments in cancer therapy.
    • Contributes to optimizing treatment protocols for improved patient outcomes in oncology.